ZTS Quote, Financials, Valuation and Earnings

Elanco Animal Health, Inc. has a net margin of 25.26% compared to Zoetis, Inc.'s net margin of -2.99%. Zoetis, Inc.'s return on equity of 57.78% beat Elanco Animal Health, Inc.'s return on equity of 0.55%.

Zoetis, Inc. has a consensus price target of $151.00, signalling upside risk potential of 18.64%. On the other hand Elanco Animal Health, Inc. has an analysts' consensus of $26.23 which suggests that it could grow by 4.09%. Given that Zoetis, Inc. has higher upside potential than Elanco Animal Health, Inc., analysts believe Zoetis, Inc. is more attractive than Elanco Animal Health, Inc..

Zoetis, Inc. has a beta of 0.962, which suggesting that the stock is 3.849% less volatile than S&P 500. In comparison Elanco Animal Health, Inc. has a beta of 1.869, suggesting its more volatile than the S&P 500 by 86.931%.

Zoetis, Inc. has a quarterly dividend of $0.53 per share corresponding to a yield of 1.6%. Elanco Animal Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis, Inc. pays 33.71% of its earnings as a dividend. Elanco Animal Health, Inc. pays out -- of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis, Inc. quarterly revenues are $2.4B, which are larger than Elanco Animal Health, Inc. quarterly revenues of $1.1B. Zoetis, Inc.'s net income of $603M is higher than Elanco Animal Health, Inc.'s net income of -$34M. Notably, Zoetis, Inc.'s price-to-earnings ratio is 21.14x while Elanco Animal Health, Inc.'s PE ratio is 345.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis, Inc. is 5.97x versus 2.73x for Elanco Animal Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 25.26% compared to Zoetis, Inc.'s net margin of -121.83%. Zoetis, Inc.'s return on equity of 57.78% beat Moderna, Inc.'s return on equity of -29.19%.

Zoetis, Inc. has a consensus price target of $151.00, signalling upside risk potential of 18.64%. On the other hand Moderna, Inc. has an analysts' consensus of $41.75 which suggests that it could fall by -16%. Given that Zoetis, Inc. has higher upside potential than Moderna, Inc., analysts believe Zoetis, Inc. is more attractive than Moderna, Inc..

Zoetis, Inc. has a beta of 0.962, which suggesting that the stock is 3.849% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Zoetis, Inc. has a quarterly dividend of $0.53 per share corresponding to a yield of 1.6%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis, Inc. pays 33.71% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis, Inc. quarterly revenues are $2.4B, which are larger than Moderna, Inc. quarterly revenues of $678M. Zoetis, Inc.'s net income of $603M is higher than Moderna, Inc.'s net income of -$826M. Notably, Zoetis, Inc.'s price-to-earnings ratio is 21.14x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis, Inc. is 5.97x versus 9.95x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 25.26% compared to Zoetis, Inc.'s net margin of -9.34%. Zoetis, Inc.'s return on equity of 57.78% beat Pfizer Inc.'s return on equity of 10.84%.

Zoetis, Inc. has a consensus price target of $151.00, signalling upside risk potential of 18.64%. On the other hand Pfizer Inc. has an analysts' consensus of $28.56 which suggests that it could grow by 6.89%. Given that Zoetis, Inc. has higher upside potential than Pfizer Inc., analysts believe Zoetis, Inc. is more attractive than Pfizer Inc..

Zoetis, Inc. has a beta of 0.962, which suggesting that the stock is 3.849% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Zoetis, Inc. has a quarterly dividend of $0.53 per share corresponding to a yield of 1.6%. Pfizer Inc. offers a yield of 6.4% to investors and pays a quarterly dividend of $0.43 per share. Zoetis, Inc. pays 33.71% of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.

Zoetis, Inc. quarterly revenues are $2.4B, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Zoetis, Inc.'s net income of $603M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Zoetis, Inc.'s price-to-earnings ratio is 21.14x while Pfizer Inc.'s PE ratio is 19.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis, Inc. is 5.97x versus 2.45x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 25.26% compared to Zoetis, Inc.'s net margin of 21.74%. Zoetis, Inc.'s return on equity of 57.78% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Zoetis, Inc. has a consensus price target of $151.00, signalling upside risk potential of 18.64%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $868.04 which suggests that it could grow by 10.95%. Given that Zoetis, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Zoetis, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Zoetis, Inc. has a beta of 0.962, which suggesting that the stock is 3.849% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Zoetis, Inc. has a quarterly dividend of $0.53 per share corresponding to a yield of 1.6%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.94 per share. Zoetis, Inc. pays 33.71% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis, Inc. quarterly revenues are $2.4B, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Zoetis, Inc.'s net income of $603M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Zoetis, Inc.'s price-to-earnings ratio is 21.14x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis, Inc. is 5.97x versus 5.93x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.